CoChat

Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis

Open access
Dowdy, David W., Cattamanchi, Adithya, Steingart, Karen R., Pai, Madhukar · 2011 · PLoS Medicine
Cited by 62

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Scaling Up Rapid Diagnostic TestsSince 2007, the World Health Organization (WHO) has approved an unprecedented number of new diagnostic tests for tuberculosis (TB) [1,2].Most recently, Xpert MTB/RIF (Cepheid, Inc.; Sunnyvale, CA), an automated polymerase chain reaction (PCR) test with high accuracy in validation studies (72%-77% sensitivity for smear-negative TB, 99% specificity) [3,4], was endorsed by WHO [5] and reduced in price [6].To impact TB globally, Xpert MTB/RIF and other diagnostics must be scaled-up across numerous clinical settings, after careful evaluation of expected costs and benefits.Unfortunately, standard cost-effectiveness analyses are ill-suited to guide local decision-makers in directing scale-up activities.We demonstrate the limitations of standard economic analyses as applied to scale-up of TB diagnostics (specifically Xpert MTB/RIF), and recommend adaptations to future analyses that will facilitate rational and effective scale-up activities.The Essay section contains opinion pieces on topics of broad interest to a general medical audience.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1001063

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 62

Metadata

Authors
Dowdy, D. W., Cattamanchi, A., Steingart, K. R., & Pai, M.
Venue
PLoS Medicine
Published
2011-07-26
Volume
8
Issue
7
Pages
e1001063
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2063243106
Cited by
62
References
4
FWCI
6.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. https://app.cochat.ai/papers/10.1371/journal.pmed.1001063
The paper
Dowdy, D. W., Cattamanchi, A., Steingart, K. R., & Pai, M. (2011). Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1001063

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.